title: Secukinumab: a promising therapeutic option in spondyloarthritis.
abstract: Psoriatic arthritis (PsA) is the second most common chronic inflammatory joint disease. Ankylosing spondylitis (AS) is another less common but equally chronic and disabling spondyloarthritis (SpA). Therapeutic agents for the treatment of these diseases have been somewhat lacking as compared with those available for rheumatoid arthritis, which represents a significant challenge for both the treating physician and the pharmaceutical industry. A promising development for our understanding of the physiopathology of PsA and AS involves new targets to interrupt IL-17 and IL-12/IL-23 pathways. Up to 30-40 % of SpA patients have inadequate or poor response, or are intolerant to anti-TNF therapies. Therefore, there has been a clear unmet medical need in an important group of these patients. As a result, new therapeutic targets have emerged for the treatment of both axial and peripheral SpA. Interleukin 17 (IL-17) is a pro-inflammatory cytokine that is increased in psoriatic lesions as well as in the synovial fluid of patients with PsA and in sites of enthesitis in SpA. IL-23 has been shown to play an important role in the polarization of CD4+ T-cells to become IL-17 producers. Based on these evidences, blockade of the cytokine IL-17 or its receptors was considered to have therapeutic implications for the treatment of psoriasis, as well as PsA and AS.This article presents a thorough review of an IL-17 A blocking agent, its mechanism of action, its clinical efficacy and its therapeutic safety.
authors.affiliation: Rheumatology Section, Department of Internal Medicine, Hospital San Antonio de Padua, Cordoba, Río Cuarto, Argentina. nanmaldonado@msn.com.
authors.forename: Hernan
authors.initials: H
authors.lastname: Maldonado-Ficco
authors.affiliation: Rheumatology Section, Department of Internal Medicine, Hospital Avellaneda, Tucumán, Argentina.
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Perez-Alamino
authors.affiliation: University of Buenos Aires, Buenos Aires, Argentina.|Rheumatology Training Program, Buenos Aires University School of Medicine, Buenos Aires, Argentina.
authors.forename: José A
authors.initials: JA
authors.lastname: Maldonado-Cocco
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D006801:Humans; D020381:Interleukin-17 / Q000037:antagonists & inhibitors; D025241:Spondylarthritis / Q000188:drug therapy*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; C508717:IL17A protein, human; D020381:Interleukin-17; C555450:secukinumab
keywords: Ankylosing spondylitis; Interleukin-17; Psoriasis; Psoriatic arthritis; Secukinumab; Spondyloarthritis